MOST Australian women of reproductive age prescribed GLP-1 receptor agonists, such as Ozempic, are not using effective contraception, despite risks during pregnancy, according to a study published in the MJA.

Researchers from Flinders University analysed data from over 18,000 women aged 18 to 49 who were first prescribed GLP-1 receptor agonists between 2011 and 2022, and found only 21% had reported using contraception.

The study also found that 2.2% of women became pregnant within six months of starting treatment with GLP1-RAs.

Interestingly, women with polycystic ovary syndrome were twice as likely to conceive, suggesting that weight loss may improve fertility, even when it is unintended.

Lead author and pharmacist, Associate Professor Luke Grzeskowiak, said that most of those starting treatment were using it for weight loss rather than diabetes, and warned that while the drugs can be helpful, they are not risk-free, especially during pregnancy.

The drugs have been linked with congenital malformations in animal studies, but effects during pregnancy have not been well studied in humans.

“We’re seeing widespread use of these medications among women of childbearing age, but very little evidence that contraception is being considered as part of routine care,” said A/Prof Grzeskowiak.

“We need to ensure that reproductive health is part of every conversation when these drugs are prescribed to any women of childbearing age.”

Read the paper HERE.

The post GLP-1 RA pregnancy risks overlooked by young women appeared first on Pharmacy Daily.